ERBB2 and allergic disease: A 45-year-old woman with metastatic HER2-positive lobular carcinoma, pretreated with trastuzumab plus pertuzumab plus docetaxel for 2 cycles (in the Cleopatra trial), switched to vinorelbine plus trastuzumab because of an allergic reaction to docetaxel, was considered non-evaluable because of a grade 3 allergic reaction occurring immediately after the beginning of the first PLD infusion.